Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 1/2 1

Status

Terminated 2Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 13Neoplasm Metastasis 10Colorectal Neoplasms 8Neoplasms 7Colonic Neoplasms 5Lung Neoplasms 4Pancreatic Neoplasms 3Carcinoma, Renal Cell 2Solid Tumors 1Rectal Neoplasms 1Kidney Neoplasms 1Healthy Adults 1Biliary Tract Neoplasms 1Advanced Solid Tumor 1

Interventions

Bevacizumab 27Leucovorin 23Fluorouracil 22Oxaliplatin 17Irinotecan 15Cetuximab 14pembrolizumab 11IFL protocol 11Panitumumab 10Folfox protocol 10Capecitabine 10Gemcitabine 7adagrasib 5Cisplatin 5Carboplatin 5Ramucirumab 4Colonoscopy 4veliparib 3spartalizumab 3selpercatinib 3regorafenib 3labetuzumab 3durvalumab 3conatumumab 3cemiplimab 3Pemetrexed 3Paclitaxel 3HMPL-013 3Drug Therapy 35,11-methenyltetrahydrohomofolate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Colonic Neoplasms × adagrasib × Clear all
NCT04793958 2026-04-27

KRYSTAL-10

Mirati Therapeutics Inc.

Phase 3 Active not recruiting
461 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05578092 2026-02-19

A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Mirati Therapeutics Inc.

Phase 1 Terminated
64 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Colorectal Neoplasms

NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Mirati Therapeutics Inc.

Phase 1/2 Active not recruiting
731 enrolled 1 FDA
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04330664 2025-04-04

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Mirati Therapeutics Inc.

Phase 1 Completed
86 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04975256 2024-12-16

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Mirati Therapeutics Inc.

Phase 1 Terminated
7 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡